NUWE

Nuwellis, Inc. (NUWE) 2025 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2025. Nuwellis, Inc. is a commercial-stage medical device company focused on advancing cardiorenal care through the development, manufacturing, and commercialization of the Aquadex System (Aquadex FlexFlow and SmartFlow). The system is indicated for ultrafiltration therapy to remove excess fluid in adult and pediatric patients (weighing 20 kg or more) with fluid overload unresponsive to diuretics. The company operates as a single reporting segment and is classified as a "smaller reporting company" and "non-accelerated filer."

Key Financial Metrics

Note: The Net Loss for 2025 includes significant non-cash financing expenses ($10.55 million) and a gain from the change in fair value of warrant liability ($4.13 million).

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased by 5.4% to $8.27 million, driven by a 2% decrease in circuit sales, lower console average selling prices, reduced international sales, and the absence of one-time prior-year SeaStar Medical sales.
• Increased Net Loss: Net loss widened to $17.5 million from $11.2 million. While operating expenses remained relatively flat, the increase in net loss was significantly impacted by financing expenses related to warrant valuations and issuance costs.
• Manufacturing Transition: The company transitioned manufacturing of the Aquadex SmartFlow Console, blood circuits, and catheters to a third-party contract manufacturer, KDI Precision Manufacturing, completing the personnel transition by December 31, 2025.
• Strategic Realignment: The company terminated the REVERSE-HF clinical trial in July 2025 to save approximately $4.0 million over 2.5 years, shifting focus to outpatient heart failure, pediatrics, and critical care. Additionally, the company exited international operations in all but four jurisdictions (Singapore, Hong Kong, Israel, and Brazil) to focus on the U.S. market.
• Capital Structure: The company executed a 1-for-42 reverse stock split in July 2025 to regain compliance with Nasdaq listing requirements. It also raised capital through a public offering in June 2025 and an At-The-Market (ATM) offering starting in September 2025.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that the company's recurring losses, accumulated deficit of $316.3 million, and need for additional capital raise substantial doubt about its ability to continue as a going concern for at least twelve months from the report date. Management believes current resources will fund operations only through the second quarter of 2026.
• Internal Control Weaknesses: Management identified two material weaknesses in internal control over financial reporting: insufficient headcount for segregation of duties and a lack of contemporaneous documentation for controls (e.g., balance sheet reconciliations, journal entries).
• Product Recall: In December 2024, the company voluntarily recalled specific lots of the AquaFlexFlow UF 500 Plus blood circuit (Class 1 recall) due to mismatch alarms that could lead to excess fluid removal. Five incidences were reported, three resulting in patient dehydration.
• Legal Proceedings: In February 2026 (subsequent event), E.F. Hutton & Co. filed a complaint alleging breach of an engagement letter regarding exclusive placement agent services. The company intends to vigorously defend itself.
• Acquisition: In January 2026, the company entered into an agreement to acquire Rendiatech Ltd., an Israeli company focused on automated kidney function monitoring, for cash, stock, and an earn-out royalty.
• Outlook: The company plans to focus on U.S. markets, specifically cardiac surgery, pediatrics, and outpatient heart failure. It expects to continue incurring losses in the near term and will require additional equity or debt financing to sustain operations beyond mid-2026.

Investor Verification Checklist

• Liquidity Runway: Verify the company's ability to raise capital before the end of Q2 2026, given the "substantial doubt" going concern warning and cash balance of only $1.1 million.
• Revenue Concentration: Confirm the stability of the top customer, which represented 13.7% of 2025 revenue, and the top ten customers, representing 49.3% of revenue.
• Manufacturing Reliance: Assess the risks associated with the sole reliance on KDI Precision Manufacturing for all assembly and production.
• Warrant Liability: Review the impact of outstanding warrants (1.33 million shares) and their potential dilution or liability reclassification on future financial statements.
• Internal Controls: Monitor the remediation progress of the two identified material weaknesses in internal controls over financial reporting.
• Regulatory Status: Track the status of the Class 1 recall and any potential FDA enforcement actions or additional quality management issues.